Hormone therapy and anti-aging: Is there an indication?;Hormontherapie und anti-aging: Gibt es eine indikation?

Internist

Volumn 49, Issue 5, 2008, Pages 570-580

  Heutling, D ^a   Lehnert, H ^b,c,d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Anti aging; DHEA; Growth hormone; Hormone replacement; Melatonin

Indexed keywords

GROWTH HORMONE; MELATONIN; PRASTERONE; TESTOSTERONE;

CANCER PREVENTION; DEGENERATIVE DISEASE; GERIATRIC CARE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; MORBIDITY; PREMATURE AGING; PREVENTION AND CONTROL; QUALITY OF LIFE; REVIEW;

AGING; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS;

EID: 43149085022     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-008-2110-3     Document Type: Review

References (68)

1. Abdu TA, Neary R, Elhadd TA et al. (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 55: 209-216
2. Anisimov VN, Zavarzina NY, Zabezhinski MA et al. (2001) Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol A Biol Sci Med Sci 56: B311-B323
3. Arlt W, Callies F, Koehler I et al. (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 86: 4686-4692
4. Bates AS, Van't Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169-1172
5. Baulieu EE, Thomas G, Legrain S et al. (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97: 4279-4284
6. Bengtsson BA, Koppeschaar HP, Abs R et al. (1999) Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J Clin Endocrinol Metab 84: 4291-4292
7. Blask DE, Dauchy RT, Sauer LA (2005) Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27: 179-188
8. Cohn L, Feller AG, Draper MW et al. (1993) Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 39: 417-425
9. Dean CE (2000) Prasterone (DHEA) and mania. Ann Pharmacother 34: 1419-1422
10. Elhadd TA, Abdu TA, Clayton R (2001) Hypopituitarism and atherosclerosis. Ann Med 33: 477-485
11. Feldman HA, Goldstein I, Hatzichristou DG et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54-61
12. Ferrari E, Cravello L, Falvo F et al. (2008) Neuroendocrine features in extreme longevity. Exp Gerontol 43: 88-94
13. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL et al. (1999) Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 84: 1527-1533
14. Hankinson SE (2005) Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24: 3-15
15. Hennessey JV, Chromiak JA, DellaVentura S et al. (2001) Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 49: 852-858
16. Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2: CD001520
17. Heutling D, Lehnert H (2005) Hormone therapy and menopause. Dtsch Med Wochenschr 130: 829-834
18. Huppert FA, Van Niekerk JK (2001) Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 4: CD000304
19. Iranmanesh A, Lizarralde G, Veldhuis JD (1991) Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73: 1081-1088
20. Iwasaki Y, Asai M, Yoshida M et al. (2004) Dehydroepiandrosterone-sulfate inhibits nuclear factor-kappaB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab 89: 3449-3454
21. Jankowski CM, Gozansky WS, Schwartz RS et al. (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91: 2986-2993
22. Jenkins PJ (2006) Cancers associated with acromegaly. Neuroendocrinology 83: 218-223
23. Johansson T, Le GP (2005) The effect of dehydroepiandrosterone sulfate and allopregnanolone sulfate on the binding of [(3)H]ifenprodil to the N-methyl-d-aspartate receptor in rat frontal cortex membrane. J Steroid Biochem Mol Biol 94: 263-266
24. Kawano H, Yasue H, Kitagawa A et al. (2003) Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88: 3190-3195
25. Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, Forsling ML (1998) Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf) 48: 31-37
26. Kroboth PD, Salek FS, Pittenger AL et al. (1999) DHEA and DHEA-S: a review. J Clin Pharmacol 39: 327-348
27. Labrie F, Diamond P, Cusan L et al. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498-3505
28. Labrie F, Luu-The V, Labrie C, Simard J (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185-212
29. Legrain S, Massien C, Lahlou N et al. (2000) Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. Clin Endocrinol Metab 85: 3208-3217
30. Lemus-Wilson A, Kelly PA, Blask DE (1995) Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer 72: 1435-1440
31. Leonsson M, Hulthe J, Oscarsson J et al. (2002) Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 57: 751-759
32. Li L, Yu H, Schumacher F et al. (2003) Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14: 721-726
33. Liu D, Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379-21388
34. Markowitz JS, Carson WH, Jackson CW (1999) Possible dihydroepiandrosterone-induced mania. Biol Psychiatry 45: 241-242
35. Mattison JA, Lane MA, Roth GS, Ingram DK (2003) Calorie restriction in rhesus monkeys. Exp Gerontol 38: 35-46
36. Morales AJ, Haubrich RH, Hwang JY et al. (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 49: 421-432
37. Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360-1367
38. Nair KS, Rizza RA, O'Brien P et al. (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647-1659
39. Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59: 551-555
40. Orentreich N, Brind JL, Vogelman JH et al. (1992) Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75: 1002-1004
41. Papadakis MA, Grady D, Black D et al. (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708-716
42. Paparrigopoulos T (2002) Melatonin response to atenolol administration in depression: indication of beta-adrenoceptor dysfunction in a subtype of depression. Acta Psychiatr Scand 106: 440-445
43. Percheron G, Hogrel JY, Denot-Ledunois S et al. (2003) Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 163: 720-727
44. Reiter WJ, Pycha A, Schatzl G et al. (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53: 590-594
45. Reiter WJ, Schatzl G, Mark I et al. (2001) Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29: 278-281
46. Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285-288
47. Roth GS, Lane MA, Ingram DK et al. (2002) Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811
48. Roth GS, Lesnikov V, Lesnikov M et al. (2001) Dietary caloric restriction prevents the age-related decline in plasma melatonin levels of rhesus monkeys. J Clin Endocrinol Metab 86: 3292-3295
49. Rudman D, Feller AG, Nagraj HS et al. (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1-6
50. Sauer LA, Dauchy RT, Blask DE (2001) Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life Sci 68: 2835-2844
51. Schwartz AG, Pashko LL (2004) Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171-187
52. Shi R, Yu H, McLarty J, Glass J (2004) IGF-I and breast cancer: a meta-analysis. Int J Cancer 111: 418-423
53. Sonntag WE, Carter CS, Ikeno Y et al. (2005) Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 146: 2920-2932
54. Sousa A, Ticku MK (1997) Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABA(A) receptor complex reveals that it may act via the picrotoxin site. J Pharmacol Exp Ther 282: 827-833
55. Srinivasan V, Pandi-Perumal SR, Maestroni GJ et al. (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7: 293-318
56. Svensson J, Bengtsson BA, Rosen T et al. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306-3312
57. Taaffe DR, Jin IH, Vu TH et al. (1996) Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81: 421-425
58. Taaffe DR, Lewis B, Marcus R (1994) Quantifying the effect of hand preference on upper limb bone mineral and soft tissue composition in young and elderly women by dual-energy X-ray absorptiometry. Clin Physiol 14: 393-404
59. Takebayashi M, Hayashi T, Su TP (2004) A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 37 (Suppl 3): S208-S213
60. Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J (2002) A case report of mania precipitated by use of DHEA. Encephale 28: 563-566
61. Vesnushkin GM, Plotnikova NA, Semenchenko AI, Anisimov VN (2006) Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res 25: 507-513
62. Villareal DT, Holloszy JO (2004) Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292: 2243-2248
63. Villareal DT, Holloszy JO (2006) DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab 291: E1003-E1008
64. Wallace JD, Cuneo RC, Baxter R et al. (1999) Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 84: 3591-3601
65. Wetterberg L, Bergiannaki JD, Paparrigopoulos T et al. (1999) Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24: 209-226
66. Wilson ST, Blask DE, Lemus-Wilson AM (1992) Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab 75: 669-670
67. Wolkowitz OM, Kramer JH, Reus VI et al. (2003) DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 60: 1071-1076
68. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489